临床试验/NCT04484142

NCT04484142已完成2 期

Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations and Progressed On or After Applicable Targeted Therapy and Platinum Based Chemotherapy (TROPION-Lung05)

Daiichi Sankyo164 个研究点分布在 5 个国家目标入组 137 人开始时间: 2021年3月30日最近更新: 2026年3月24日

适应症

干预措施

试验速览

阶段: 2 期
状态: 已完成
发起方: Daiichi Sankyo
入组人数: 137
试验地点: 164
主要终点: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验相关资讯

研究概览

简要总结

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.

详细描述

This study will evaluate DS-1062a 6.0 mg/kg in participants with advanced or metastatic NSCLC with actionable genomic alterations and who have been previously been treated with 1 platinum-containing therapy and 1 or more lines of targeted therapy. The study will be divided into 3 periods: Screening Period, Treatment Period, and Follow-up Period. The primary analysis of Objective Response Rate (ORR) by blinded Independent Central Review (BICR) will be conducted after all participants either have been followed for at least 9 months after the start of study treatment or have discontinued from the study, whichever occurs first.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Participants eligible for inclusion in the study must meet all inclusion criteria for this study.
•Sign and date the inform consent form (ICF) prior to the start of any study- specific qualification procedures.
•Adults ≥18 years (if the legal age of consent is >18 years old, then follow local regulatory requirements)
•Has pathologically documented NSCLC that:
•Has stage IIIB, IIIC, or stage IV NSCLC disease at the time of enrollment (based on the American Joint Committee on Cancer, Eighth Edition).
•Has one or more of the following documented activating genomic alterations: EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, or RET.
•KRAS mutations in the absence of any of the genomic alterations specified above will be excluded.
•Overexpression of EGFR, in the absence of activating mutations, is NOT sufficient for enrollment.
•Participants who have not received osimertinib should be evaluated for the presence of EGFR T790M mutation after relapse/progression on/after the most recent EGFR tyrosine kinase inhibitor (TKI), unless the participant is already known to be positive with document results for this mutation or unless osimertinib is not locally approved.
•Has documentation of radiographic disease progression while on or after receiving the most recent treatment regimen for advanced or metastatic NSCLC.
•Participant must meet the following for advanced or metastatic NSCLC:
•Has been treated with at least one but no more than two cytotoxic agent-containing therapy in the metastatic setting:
•One platinum-containing regimen (either as monotherapy or combination therapy).
•May have received up to one additional line of cytotoxic agent-containing therapy.
•Those who received a platinum-containing regimen as adjuvant therapy for early stage disease must have relapsed or progressed while on the treatment or within 6 months of the last dose OR received at least one additional course of platinum-containing therapy (which may or may not be same as in the adjuvant setting) for relapsed/progressive disease.
•May have received up to one checkpoint inhibitor (CPI)-containing regimen (may be in combination with a cytotoxic agent as part of a regimen described above or as an additional CPI regimen without a cytotoxic agent).
•Has been treated with 1 or more lines of non-CPI targeted therapy that is locally approved for the participant's applicable genomic alteration at the time of screening:
•Those who received a targeted agent for the applicable genomic alterations in the study as adjuvant therapy for early stage disease must have relapsed or progressed while on the treatment or within 6 months of the last dose OR received at least one additional course of targeted therapy for the same genomic alterations (which may or may not be same agent used in the adjuvant setting) for relapsed/progressive disease.
•Participants who have been treated with a prior TKI must receive additional targeted therapy, if clinically appropriate, for the genomic alterations that are considered amenable or the participant will not be allowed in the study.
•Must undergo a mandatory pre-treatment tumor biopsy procedure or if available, a tumor biopsy that was recently collected (within 3 months of screening) after completion of the most recent anticancer treatment regimen and that has a minimum of 10 × 4 micron sections or a tissue block equivalent of 10 × 4 micron sections may be substituted for the mandatory biopsy collected during screening.
•Measurable disease based on local imaging assessment using RECIST v1.
•Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 - 1 at screening.

排除标准

•Participants meeting any exclusion criteria for this study will be excluded from this study.
•Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Participants with clinically inactive brain metastases may be included in the study.
•Has leptomeningeal carcinomatosis.
•Has prior treatment with:
•Any chemotherapeutic agent targeting topoisomerase I, including antibody drug conjugate (ADC) containing such agent.
•TROP2-targeted therapy.
•Uncontrolled or significant cardiovascular disease:
•History of myocardial infarction within 6 months prior to Cycle 1 Day
•History of uncontrolled angina pectoris within 6 months prior to Cycle 1 Day
•Symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV) at screening. Participants with a history of Class II to IV CHF prior to screening must have returned to Class I CHF and have LVEF ≥50% (by either an ECHO or MUGA scan within 28 days of Cycle 1 Day 1) in order to be eligible.
•History of serious cardiac arrhythmia requiring treatment.
•LVEF <50% or institutional lower limit of normal by ECHO or MUGA scan.
•Uncontrolled hypertension (resting systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg).
•Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
•Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
•Clinically significant corneal disease.
•Has other primary malignancies, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated, with no evidence of disease for ≥3 years.

研究组 & 干预措施

DS-1062a 6.0 mg/kg

Experimental

Participants will receive 6.0 mg/kg of DS-1062a

干预措施: DS-1062a (Drug)

结局指标

主要结局

Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR)

时间窗: From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.

ORR is defined as the proportion of participants with a best overall response of confirmed complete response (CR) or confirmed partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

次要结局

Duration of Response (DOR)(From baseline up to approximately 24 months)
Progression-free Survival (PFS)(From baseline up to approximately 24 months)
Pharmacokinetic Parameter Maximum Concentration (Cmax)(From baseline up to approximately 24 months)
Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC)(From baseline up to approximately 24 months)
Percentage of Participants Who Reported Treatment-emergent Adverse Events (TEAE)(From baseline up to approximately 24 months)
Overall Survival (OS)(From baseline up to approximately 24 months)
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)(From baseline up to approximately 24 months)

研究者

发起方

Daiichi Sankyo

申办方类型

Industry

责任方

Sponsor

研究点 (164)

Loading locations...

相似试验

进行中（未招募）

1 期

Phase 2 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic AlterationsAdvanced or Metastatic Non-small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864

CTIS2024-511449-21-00Daiichi Sankyo Inc.24

进行中（未招募）

1 期

Phase 2 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic AlterationsAdvanced or Metastatic Non-small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-002774-27-FRDaiichi Sankyo, Inc.150

进行中（未招募）

1 期

Phase 2 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations

EUCTR2020-002774-27-NLDaiichi Sankyo, Inc.150

进行中（未招募）

2 期

Phase 2 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations

JPRN-jRCT2041200097Inoguchi Akihiro150

进行中（未招募）

1 期

Phase 2 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic AlterationsAdvanced or Metastatic Non-small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-002774-27-HUDaiichi Sankyo, Inc.150